{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:36:41Z","timestamp":1790807801411,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"SoMoPro II Programme","award":["3SGA5789"],"award-info":[{"award-number":["3SGA5789"]}]},{"name":"CEITEC 2020","award":["LQ1601"],"award-info":[{"award-number":["LQ1601"]}]},{"DOI":"10.13039\/501100010653","name":"Masaryk University, Brno, Czechia","doi-asserted-by":"publisher","award":["MUNI\/A\/1132\/2017"],"award-info":[{"award-number":["MUNI\/A\/1132\/2017"]}],"id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education, Youth and Sports of Czech Republic","doi-asserted-by":"publisher","award":["LO1212"],"award-info":[{"award-number":["LO1212"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CzBI_IS","award":["LM2015062"],"award-info":[{"award-number":["LM2015062"]}]},{"name":"Piano triennale per la Ricerca - Linea Intervento 2, University of Catania, Italy"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.neuropharm.2018.11.035","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T17:21:35Z","timestamp":1543252895000},"page":"212-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia"],"prefix":"10.1016","volume":"146","author":[{"given":"Tibor","family":"Stark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-0799","authenticated-orcid":false,"given":"Jana","family":"Ruda-Kucerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Arturo","family":"Iannotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"D'Addario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Pekarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Drazanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Babinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giurdanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Salomone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sulcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Maccarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten T.","family":"Wotjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Zenon","family":"Starcuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Mechoulam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Marzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Micale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.11.035_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0149-7634(03)00005-8","article-title":"Trajectories of brain development: point of vulnerability or window of opportunity?","volume":"27","author":"Andersen","year":"2003","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study","volume":"325","author":"Arseneault","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib3","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1111\/febs.12329","article-title":"In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system","volume":"280","author":"Bari","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.euroneuro.2017.11.013","article-title":"Adolescent environmental enrichment prevents the emergence of schizophrenia-like abnormalities in a neurodevelopmental model of schizophrenia","volume":"28","author":"Bator","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","article-title":"Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington's disease","volume":"52","author":"Bisogno","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1017\/S1461145712000739","article-title":"Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia","volume":"16","author":"Brown","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-012-2878-7","article-title":"Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats","volume":"226","author":"Campos","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib11","series-title":"An Evaluation and Interpretation of Reproductive Endpoints for Human Risk Assessment","first-page":"10","article-title":"Endpoints of reproductive system development","author":"Clark","year":"1999"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2017.01.022","article-title":"A preliminary study of endocannabinoid system regulation in psychosis: distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia","volume":"188","author":"D'Addario","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptin-regulated endocannabinoids are involved in maintaining food intake","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0924-977X(01)00084-0","article-title":"Placebo affects the performance of rats in models of depression: is it a good control for behavioral experiments?","volume":"11","author":"Drago","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib16","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/npp.2013.101","article-title":"Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia","volume":"38","author":"Du","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib17","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1038\/npp.2016.42","article-title":"Amygdala hyperactivity in MAM model of schizophrenia is normalized by peripubertal diazepam administration","volume":"41","author":"Du","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib19","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u0394 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/phar.1780","article-title":"Current status and prospects for cannabidiol preparations as new therapeutic agents","volume":"36","author":"Fasinu","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/sj.npp.1300625","article-title":"Cognitive deficits caused by late gestational disruption of neurogenesis in rats: a preclinical model of schizophrenia","volume":"30","author":"Flagstad","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib23","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/sj.npp.1300516","article-title":"Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens","volume":"29","author":"Flagstad","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuropharm.2018.03.001","article-title":"The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling","volume":"135","author":"Foga\u00e7a","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.euroneuro.2013.10.012","article-title":"Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience","volume":"24","author":"Foga\u00e7a","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neubiorev.2016.05.030","article-title":"Adolescence as a period of vulnerability and intervention in schizophrenia: insights from the MAM model","volume":"70","author":"Gomes","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2015.01.015","article-title":"Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol","volume":"164","author":"Gomes","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S1461145710000209","article-title":"Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine","volume":"14","author":"Guidali","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.lfs.2004.01.015","article-title":"Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum","volume":"75","author":"Guimar\u00e3es","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0006-3223(00)00919-7","article-title":"Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia","volume":"48","author":"Heckers","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","article-title":"Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders","volume":"62","author":"Iannotti","year":"2016","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.plefa.2013.06.002","article-title":"Analysis of the \u201cendocannabinoidome\u201d in peripheral tissues of obese Zucker rats","volume":"89","author":"Iannotti","year":"2013","journal-title":"Prostaglandins, Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nrd2775","article-title":"End of the line for cannabinoid receptor 1 as an anti-obesity target?","volume":"7","author":"Jones","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbr.2017.05.065","article-title":"The MAM-E17 schizophrenia rat model: comprehensive behavioral analysis of pre-pubertal, pubertal and adult rats","volume":"332","author":"K\u00e1llai","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib37","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.schres.2006.07.023","article-title":"Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness","volume":"88","author":"Koethe","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1095\/biolreprod17.2.298","article-title":"Preputial separation as an external sign of pubertal development in the male rat","volume":"17","author":"Korenbrot","year":"1977","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1574889809666140307115532","article-title":"Therapeutic potential of cannabinoids in schizophrenia","volume":"9","author":"Kucerova","year":"2014","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib41","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.neuroscience.2006.08.004","article-title":"Peri-pubertal maturation after developmental disturbance: a model for psychosis onset in the rat","volume":"143","author":"Le Pen","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbr.2009.01.031","article-title":"Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia","volume":"204","author":"Lodge","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib44","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/FBP.0000000000000068","article-title":"Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain","volume":"25","author":"Marco","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S0954579400003138","article-title":"The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave","volume":"12","author":"Marenco","year":"2000","journal-title":"Dev. Psychopathol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbr.2015.02.023","article-title":"Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: contribution of 5HT\u2081A receptors and stressful experiences","volume":"286","author":"Marinho","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib47","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","article-title":"Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain","volume":"11","author":"Marsicano","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib48","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hup.2350","article-title":"Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial","volume":"28","author":"Mas","year":"2013","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2007.06.011","article-title":"Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins","volume":"54","author":"Matias","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib51","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/0269881117704988","article-title":"Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: a preliminary investigation","volume":"31","author":"McLean","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/npp.2008.98","article-title":"Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels","volume":"34","author":"Micale","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00441-013-1692-9","article-title":"Leading compounds for the validation of animal models of psychopathology","volume":"354","author":"Micale","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jpsychires.2017.02.002","article-title":"Extinction of avoidance behavior by safety learning depends on endocannabinoid signaling in the hippocampus","volume":"90","author":"Micale","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives","volume":"15","author":"Millan","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/01.pra.0000435036.83426.94","article-title":"Early intervention and the treatment of prodrome in schizophrenia: a review of recent developments","volume":"19","author":"Mokhtari","year":"2013","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.biopsych.2006.01.003","article-title":"A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia","volume":"60","author":"Moore","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2014.04.014","article-title":"The dual blocker of FAAH\/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis","volume":"87","author":"Navarria","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib59","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/npp.2017.40","article-title":"Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) rat model","volume":"42","author":"Osborne","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib60","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","article-title":"A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia","volume":"72","author":"Osborne","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pnpbp.2017.10.004","article-title":"DNA methylation and antipsychotic treatment mechanisms in schizophrenia: progress and future directions","volume":"81","author":"Ovenden","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib62","doi-asserted-by":"crossref","first-page":"57077","DOI":"10.18632\/oncotarget.10976","article-title":"Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival","volume":"7","author":"Panza","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib63","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.schres.2016.02.004","article-title":"Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia","volume":"172","author":"Peres","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.112.193201","article-title":"Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia","volume":"343","author":"Perez","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib66","first-page":"241","article-title":"Prediction and prevention of the first psychotic episode: new directions and opportunities","volume":"10","author":"Piras","year":"2014","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib67","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1038\/bjp.2008.24","article-title":"Modelling prefrontal cortex deficits in schizophrenia: implications for treatment","volume":"153","author":"Pratt","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/nlme.2001.4003","article-title":"The effects of prelimbic and infralimbic lesions on working memory for visual objects in rats","volume":"77","author":"Ragozzino","year":"2002","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib69","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neubiorev.2017.02.006","article-title":"Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: implications for novel schizophrenia treatments","volume":"75","author":"Renard","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.brainres.2010.04.031","article-title":"The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling","volume":"1343","author":"Robinson","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib71","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.2174\/138161212802884690","article-title":"Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies","volume":"18","author":"Roser","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/15622970801908047","article-title":"Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists","volume":"11","author":"Roser","year":"2010","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.tips.2007.10.006","article-title":"Allosterism and cannabinoid CB(1) receptors: the shape of things to come","volume":"28","author":"Ross","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/15622975.2016.1190032","article-title":"Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats","volume":"18","author":"Ruda-Kucerova","year":"2017","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12640-017-9718-9","article-title":"Suppression of methamphetamine self-administration by ketamine pre-treatment is absent in the methylazoxymethanol (MAM) rat model of schizophrenia","volume":"32","author":"Ruda-Kucerova","year":"2017","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib76","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3389\/fphar.2017.00399","article-title":"Cannabinoids and vanilloids in schizophrenia: neurophysiological evidence and directions for basic research","volume":"8","author":"Ruggiero","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib77","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nbd.2012.11.020","article-title":"Endocannabinoid system: potential novel targets for treatment of schizophrenia","volume":"53","author":"Saito","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib78","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib79","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/npp.2013.81","article-title":"Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB\u2081 receptors: implications for schizophrenia","volume":"38","author":"Seillier","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib80","doi-asserted-by":"crossref","first-page":"16003","DOI":"10.1038\/npjschz.2016.3","article-title":"Early interventions in risk groups for schizophrenia: what are we waiting for?","volume":"2","author":"Sommer","year":"2016","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib81","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.pnpbp.2009.07.001","article-title":"Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats","volume":"33","author":"Tamburella","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib82","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/ejn.12561","article-title":"Cannabinoid receptor type 1 receptors on GABAergic vs. glutamatergic neurons differentially gate sex-dependent social interest in mice","volume":"40","author":"Terzian","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnbeh.2011.00049","article-title":"The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors","volume":"5","author":"Terzian","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib84","doi-asserted-by":"crossref","first-page":"12330","DOI":"10.1523\/JNEUROSCI.2808-11.2011","article-title":"Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia","volume":"31","author":"Valenti","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib85","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jcp.25914","article-title":"HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals","volume":"233","author":"Ve\u010de\u0159a","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib86","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0031-9384(02)00936-8","article-title":"Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction","volume":"77","author":"Volk","year":"2002","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib87","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","article-title":"Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia","volume":"122","author":"Young","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib88","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1476-5381.2012.02095.x","article-title":"Chronic blockade of CB 1 receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation","volume":"167","author":"Zamberletti","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib89","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S1461145710001185","article-title":"Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251","volume":"15","author":"Zamberletti","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib90","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nn.2773","article-title":"Causal role of the prefrontal cortex in top-down modulation of visual processing and working memory","volume":"14","author":"Zanto","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.11.035_bib91","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/npp.2013.110","article-title":"Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia","volume":"38","author":"Zimmerman","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.11.035_bib92","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02244189","article-title":"Effects of cannabidiol in animal models predictive of antipsychotic activity","volume":"104","author":"Zuardi","year":"1991","journal-title":"Psychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818308761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818308761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T11:23:45Z","timestamp":1656069825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818308761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":92,"alternative-id":["S0028390818308761"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.11.035","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}